A detailed history of D. E. Shaw & Co., Inc. transactions in Dynavax Technologies Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,431,359 shares of DVAX stock, worth $17.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,431,359
Holding current value
$17.4 Million
% of portfolio
0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $5.93 Million - $6.86 Million
590,476 Added 70.22%
1,431,359 $15.9 Million
Q2 2024

Aug 14, 2024

BUY
$10.73 - $12.58 $5.35 Million - $6.28 Million
498,845 Added 145.84%
840,883 $9.44 Million
Q1 2024

May 15, 2024

SELL
$11.7 - $14.98 $1.97 Million - $2.52 Million
-168,219 Reduced 32.97%
342,038 $4.24 Million
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $4.05 Million - $4.63 Million
-309,353 Reduced 37.74%
510,257 $7.13 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $214,766 - $254,695
16,991 Added 2.12%
819,610 $12.1 Million
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $2.33 Million - $3.12 Million
236,727 Added 41.83%
802,619 $10.4 Million
Q1 2023

May 15, 2023

SELL
$9.44 - $11.88 $543,602 - $684,109
-57,585 Reduced 9.24%
565,892 $5.55 Million
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $1.79 Million - $2.32 Million
174,351 Added 38.82%
623,477 $6.63 Million
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $1.93 Million - $3.39 Million
-194,282 Reduced 30.2%
449,126 $4.69 Million
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $5.65 Million - $9.74 Million
-758,993 Reduced 54.12%
643,408 $8.1 Million
Q1 2022

May 16, 2022

SELL
$9.75 - $14.44 $6.62 Million - $9.81 Million
-679,311 Reduced 32.63%
1,402,401 $15.2 Million
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $739,693 - $1.18 Million
56,165 Added 2.77%
2,081,712 $29.3 Million
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $9.65 Million - $20.9 Million
1,053,737 Added 108.43%
2,025,547 $38.9 Million
Q2 2021

Aug 16, 2021

BUY
$7.25 - $10.99 $4.02 Million - $6.09 Million
554,266 Added 132.74%
971,810 $9.57 Million
Q1 2021

May 17, 2021

BUY
$4.57 - $11.18 $1.86 Million - $4.55 Million
407,244 Added 3953.83%
417,544 $4.1 Million
Q4 2020

Feb 16, 2021

SELL
$3.73 - $5.6 $35,606 - $53,457
-9,546 Reduced 48.1%
10,300 $46,000
Q3 2020

Nov 16, 2020

SELL
$4.32 - $11.7 $1.63 Million - $4.41 Million
-377,318 Reduced 95.0%
19,846 $86,000
Q2 2020

Aug 14, 2020

SELL
$2.94 - $9.1 $3.69 Million - $11.4 Million
-1,255,712 Reduced 75.97%
397,164 $3.52 Million
Q1 2020

May 15, 2020

BUY
$2.27 - $6.2 $1.32 Million - $3.6 Million
580,564 Added 54.14%
1,652,876 $5.83 Million
Q4 2019

Feb 14, 2020

SELL
$3.46 - $6.93 $142,673 - $285,758
-41,235 Reduced 3.7%
1,072,312 $6.13 Million
Q3 2019

Nov 14, 2019

SELL
$2.69 - $4.85 $1.75 Million - $3.16 Million
-650,880 Reduced 36.89%
1,113,547 $3.98 Million
Q2 2019

Aug 14, 2019

SELL
$3.65 - $7.89 $2.05 Million - $4.44 Million
-562,285 Reduced 24.17%
1,764,427 $7.04 Million
Q1 2019

May 15, 2019

BUY
$7.08 - $12.09 $227,919 - $389,201
32,192 Added 1.4%
2,326,712 $17 Million
Q4 2018

Feb 14, 2019

BUY
$8.14 - $13.28 $1.57 Million - $2.56 Million
192,770 Added 9.17%
2,294,520 $21 Million
Q3 2018

Nov 14, 2018

BUY
$11.85 - $16.0 $3.49 Million - $4.72 Million
294,790 Added 16.31%
2,101,750 $26.1 Million
Q2 2018

Aug 14, 2018

BUY
$15.15 - $20.75 $2.43 Million - $3.33 Million
160,677 Added 9.76%
1,806,960 $27.6 Million
Q1 2018

May 15, 2018

SELL
$14.65 - $19.9 $161,281 - $219,079
-11,009 Reduced 0.66%
1,646,283 $32.7 Million
Q4 2017

Feb 14, 2018

SELL
$17.3 - $24.08 $10.3 Million - $14.4 Million
-597,802 Reduced 26.51%
1,657,292 $31 Million
Q3 2017

Nov 14, 2017

BUY
$15.2 - $21.5 $34.3 Million - $48.5 Million
2,255,094
2,255,094 $48.5 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.54B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.